SKY-0515

DRUG3 trials

Sponsors

Skyhawk Therapeutics, Inc.

Conditions

Huntington DiseaseHuntington's Disease (HD)Huntingtons Disease

Phase 2

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

Active, not recruitingNCT06873334

Skyhawk Therapeutics, Inc.Huntington Disease, Huntingtons Disease

Start: 2025-05-27End: 2027-12-01Target: 120Updated: 2026-05-01

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

RecruitingNCT07378644

Skyhawk Therapeutics, Inc.Huntington Disease

Start: 2026-01-06End: 2029-08-01Target: 400Updated: 2026-09-17

An Extension of SKY-0515 in Participants With Huntington's Disease

Enrolling by invitationNCT07537075

Skyhawk Therapeutics, Inc.Huntington's Disease (HD)

Start: 2026-04-10End: 2029-12-01Target: 500Updated: 2026-07-24